News Search Results
Mar 09, 2026, 06:00 ET Phothera Launches Guided Mode for Home Phototherapy Treatments for Chronic Skin Conditions
leading manufacturer of FDA-cleared light therapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today announced the availability of Guided Mode, a next-generation on-device app designed to simplify and standardize home phototherapy.
More news about: Phothera
Mar 06, 2026, 07:03 ET CARsgen Therapeutics Announces 2025 Annual Results
specificity. KJ-C2529 is an in vivo CAR T-cell product candidate against CD19/CD20 deploying our CARvivo™ platform for the treatment of B-cell lymphoma. An IIT is expected to be initiated in 2026 for the treatment of R/R B-NHL.Expand CAR-T commercial manufacturing baseCARsgen is
More news about: CARsgen Therapeutics
Mar 05, 2026, 07:56 ET GNTbm's self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials
Patients with Advanced Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma.GNTbm independently developed the epigenetic immune-activating new drug GNTbm-38, which has global development rights. After five years of
More news about: Great Novel Therapeutics Biotech & Medicals Corporation
Mar 05, 2026, 07:35 ET 華上生醫自主開發抗癌新藥GNTbm-38獲得美國FDA臨床一期試驗的IND核准
GNTbm‑38 in Adult Patients with Advanced Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma.華上生醫自主研發擁有全球開發權利的表觀遺傳免疫活化劑新藥GNTbm-38，在歷經5年開發，完成符合美國法規要求的臨床前研究，並在2026年1月30日（美國時間）完成美國FDA的臨床一期試驗的IND申請，經過審查與意見回覆，在2026年2月28日（美國時間）獲得核准，可以進入臨床一期試驗。
More news about: 華上生醫
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
LBCLPresentation ID: 677608Abstract ID: 296369About Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30%–40% of newly diagnosed cases in the United States. DLBCL
More news about: Citius Oncology, Inc.
Mar 03, 2026, 16:05 ET Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
approval from the European Commission (EC) to expand the label of Breyanzi® as a third line treatment for relapsed or refractory follicular lymphoma. Lastly, in late December, Cryoport's customer Inovio Pharmaceuticals' BLA filing for INO-3107 was accepted by the FDA as a potential treatment for
More news about: Cryoport, Inc.
Mar 03, 2026, 14:36 ET Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
LeukemiaLymphomaMyelomaBy Therapy TypeChemotherapyImmunotherapyTargeted TherapyTyrosine kinase inhibitorsProteasome inhibitorsB-cell lymphoma-2 protein inhibitorsIsocitrate
More news about: Credence Research Inc.
Mar 03, 2026, 07:59 ET Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)
agency to discuss a path forward that achieves accelerated approval of tabelecleucel in R/R EBV+ PTLD. People living with this ultra-rare form of lymphoma urgently need an FDA-approved treatment option as none currently exist," said Adriana Herrera, Chief Executive Officer of Pierre Fabre Pharmaceuticals
More news about: Pierre Fabre Pharmaceuticals
Mar 03, 2026, 07:15 ET ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Mar 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Mar 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
multiple myeloma (MM).- In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved indications have been included in the national reimbursement scheme.SHANGHAI
More news about: Antengene Corporation Limited
Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Innovent Biologics.About Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.[7]
More news about: Innovent Biologics
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
immune system problems. Olumiant may increase your risk of lymphoma and other cancers, including skin cancers. People taking a medicine in the class of medicines called JAK inhibitors have a higher risk of certain cancers, including lymphoma and lung cancer, especially if you are a current or past smoker.
More news about: Eli Lilly and Company
Feb 26, 2026, 11:30 ET Children's Hospital of Philadelphia and Penn Medicine Launch First CRISPR-Based Platform to Pinpoint Drivers of Acute Myeloid Leukemia in Patient Cells
Leukemia and Lymphoma Program at CHOP.This work was supported by the St. Jude Children's Research Hospital Collaborative Research Consortium on Novel Therapies
More news about: Children's Hospital of Philadelphia
Feb 26, 2026, 07:30 ET Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
More news about: SOLIGENIX, INC.
Feb 25, 2026, 08:10 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
submission in France on track; routine clinical use expected by Q4 2026.Veterinary Breakthrough: 100% specificity achieved in Feline Lymphoma study; $5M milestone payment anticipated.Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed
More news about: VolitionRx Limited
Feb 25, 2026, 08:00 ET Immunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
Marrow" published in the European Journal of Haematology, evaluated the performance of SeptiCyte RAPID in patients with acute leukemia, B–cell lymphoma and multiple myeloma after bone marrow stem cell transplantation.Key FindingsElevated SeptiScores® were associated
More news about: Immunexpress, Inc.
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
major risk factor for peptic ulcer disease (90% of cases)6 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma7. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients
More news about: RedHill Biopharma Ltd.
Feb 25, 2026, 07:00 ET CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases) and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H.
More news about: Cumberland Pharmaceuticals Inc.
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
with the FDA removing previous limitations of use in relapsed or refractory primary central nervous system lymphoma. Yescarta is now the only CAR T-cell therapy approved for large B-cell lymphoma with this designation."This update to the axi-cel prescribing information provides clinicians with
More news about: USA News Group
Feb 24, 2026, 07:30 ET Soligenix to Present at BIO Investment & Growth Summit
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
More news about: SOLIGENIX, INC.
Feb 24, 2026, 07:15 ET ADC Therapeutics to Participate in March Investor Conferences
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Feb 23, 2026, 14:53 ET Sun Life to proactively offer second opinions on cancer diagnoses when members file a cancer-related claim
Report, the average annual cost of a cancer claim ranged from about $235,000 for malignant neoplasm ("solid" cancers) to over $300,000 for leukemia, lymphoma, and multiple myeloma (blood cancers). While ECR is already available through an employer's Sun Life medical stop-loss policy, members can now receive
More news about: Sun Life U.S.
Feb 23, 2026, 07:15 ET ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA